(RTTNews) - Spice maker McCormick & Co. Inc. (MKC) announced Tuesday its agreement to combine with consumer goods major Unilever Plc.'s (UL, ULVR.L) Foods business excluding India and other excluded businesses. In the transaction, Unilever will receive $15.7 billion in cash, and
(RTTNews) - Spice maker McCormick & Co. Inc. (MKC) announced Tuesday its agreement to combine with consumer goods major Unilever Plc.'s (UL, ULVR.L) Foods business excluding India and other excluded businesses. In the transaction, Unilever will receive $15.7 billion in cash, and
Caribou Biosciences ( CRBU ) added ~9% in the premarket on Tuesday after the company announced that the U.S. FDA issued the Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T cell therapy, CB-011. An allogeneic anti-BCMA CAR-T cell therapy, CB-011, is currently undergoing a Phase 1 trial called CaMMouflage for adults with relapsed or refractory multiple myeloma. Berkeley, Cali...
Caribou Biosciences ( CRBU ) added ~9% in the premarket on Tuesday after the company announced that the U.S. FDA issued the Regenerative Medicine Advanced Therapy (RMAT) designation for its CAR-T cell therapy, CB-011. An allogeneic anti-BCMA CAR-T cell therapy, CB-011, is currently undergoing a Phase 1 trial called CaMMouflage for adults with relapsed or refractory multiple myeloma. Berkeley, California-based Caribou ( CRBU ) noted that the FDA's decision was based on previously disclosed data from CaMMouflage, which indicated a 92% overall response rate in a review of 12 BCMA-naïve patients with r/r MM. The FDA’s RMAT designation aims to expedite the development and review of regenerative medicines such as cell therapies targeted at serious or life-threatening conditions. Developers can receive intensive regulatory guidance and be eligible for the FDA’s priority and rolling reviews for RMAT-designated drugs. They can even secure potential accelerated approvals if those treatments meet the required clinical standards. More on Caribou Bioscience Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value Caribou Biosciences, Inc. (CRBU) Presents at Leerink Global Healthcare Conference 2026 Transcript Caribou Biosciences, Inc. (CRBU) Presents at 2026 Tandem Meetings of ASTCT and CIBMTR - Slideshow Caribou Bioscience GAAP EPS of -$0.28 beats by $0.04, revenue of $3.94M beats by $1.98M Caribou Biosciences a new buy at Clear Street on CAR-T pipeline
Kenon ( KEN ) declares $3.85/share annual dividend . Forward yield 4.82% Payable April 20; for shareholders of record April 13; ex-div April 13. See KEN Dividend Scorecard, Yield Chart, & Dividend Growth. More on Kenon Dividend scorecard for Kenon Financial information for Kenon
Kenon ( KEN ) declares $3.85/share annual dividend . Forward yield 4.82% Payable April 20; for shareholders of record April 13; ex-div April 13. See KEN Dividend Scorecard, Yield Chart, & Dividend Growth. More on Kenon Dividend scorecard for Kenon Financial information for Kenon
Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout Futures are higher on a WSJ report that Trump is considering exiting the middle east conflict even if the Strait of Hormuz is not reopened; but the market is deciding whether this is a genuine intent to leave or another feint given the previous US attacks during negotiations and that Trump has yet to adjust his Apr...
Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout Futures are higher on a WSJ report that Trump is considering exiting the middle east conflict even if the Strait of Hormuz is not reopened; but the market is deciding whether this is a genuine intent to leave or another feint given the previous US attacks during negotiations and that Trump has yet to adjust his Apr 6 deadline. As of 8:00am, S&P futures are 1.1% higher, at session after approaching correction territory yesterday. Nasdaq futures rise 1%, with memory stocks lagging amid reports of DRAM prices plunging as much as 30% . In premarket trading, Mag7 names are higher as part of an ‘Everything Rally’ with bids to both Cyclicals and Defensives. In global markets, South Korea’s Kospi index slid 4.3%, entering a bear market as it extended its drop from a February high to 20%. SK Hynix Inc. slumped more than 7%. Bond yields are down 3-5bp, with the 10Y yield down to 4.30% after nearly hitting 4.50% two days ago; the Dollar is also lower. Commodities are mixed with crude/gasoline mixed (US avg price rises above $4/gal vs. $2.98 one month ago), after fading an earlier bounce, highlighting the paralysis created by the continually shifting White House statements. Precious metals are rallying as base metals are mixed, and Ags are bid. The macro data focus will be on JOLTS and Consumer Confidence. In premarket trading, Mag 7 stocks are all green (Meta +1.5%, Microsoft +1.6%, Alphabet +1.4%, Amazon +1.5%, Apple +0.8%, Nvidia +1.3%, Tesla +1%) Apellis Pharmaceuticals Inc. (APLS) soars 138% after Biogen Inc. agreed to acquire the company for $5.6 billion. Centessa Pharmaceuticals (CNTA) rises 48% after Eli Lilly & Co. agreed to buy the sleep drug maker in a deal worth up to $7.8 billion. FactSet Research Systems (FDS) gains 6% after the financial data company boosted its adjusted earnings-per-share forecast for the full year. It also reported adjusted EPS and revenue for the second quarter...
Enhanced Transparency, Rapid Geographic Expansion, and Stellantis-Backed Mobility Platform Position Company for Next Phase of Growth (OTC: DWAY) Enhanced Transparency, Rapid Geographic Expansion, and Stellantis-Backed Mobility Platform Position Company for Next Phase of Growth (OTC: DWAY)
Enhanced Transparency, Rapid Geographic Expansion, and Stellantis-Backed Mobility Platform Position Company for Next Phase of Growth (OTC: DWAY) Enhanced Transparency, Rapid Geographic Expansion, and Stellantis-Backed Mobility Platform Position Company for Next Phase of Growth (OTC: DWAY)
Torsten Asmus/iStock via Getty Images By Paolo Pizzoli , Senior Economist, Italy, Greece Inflation accelerates as energy push outweighs leisure and tourism drag Italian inflation accelerated in March to 1.7% (from 1.5% in February), according to Istat preliminary data, slightly below expectations. Unsurprisingly, at the heart of the acceleration were regulated and non-regulated energy prices toget...
Torsten Asmus/iStock via Getty Images By Paolo Pizzoli , Senior Economist, Italy, Greece Inflation accelerates as energy push outweighs leisure and tourism drag Italian inflation accelerated in March to 1.7% (from 1.5% in February), according to Istat preliminary data, slightly below expectations. Unsurprisingly, at the heart of the acceleration were regulated and non-regulated energy prices together with fresh food, which outweighed the deceleration in leisure, restaurants, and accommodation services. If the energy push is the inevitable consequence of the war in the Middle East on energy and fuel prices, the slowdown in the leisure and accommodation components likely reflects a normalisation of prices after the boost seen in February with the Milano Cortina Winter Olympics. The latter disinflationary boost, which helped push core inflation back to 1.9% (from 2.4% in February), looks set to disappear in April. Fuel push already there, electricity will accelerate soon With the impact of the Middle East war hitting first international oil and gas prices, the shock has been apparent in the transportation component, where petrol and diesel fuel prices are nested, with a combined weight of more than 4% in the total inflation basket. Gas prices edged up 5.9% on the month, and electricity prices gained a meagre 0.5% on the month, a normal delay due to the price formation mechanism, but that will soon accelerate. ARERA, the national energy and grid authority, pre-announced yesterday that energy bills for disadvantaged households will increase by 8% starting from the second quarter. Pass-through unfolding for manufacturers, but little evidence of wage-price spiral Looking ahead, it seems inevitable that pass-through will continue, particularly in sectors feeling the impact of the war on energy costs and supply chains. In the March manufacturing business survey, the pricing intention component accelerated markedly, reaching the highest level since March 2023. Pricing intenti...
Monty Rakusen/DigitalVision via Getty Images Market review and outlook Global equities rose in Q4, closing 2025 on a positive note. Markets gained on robust spending on AI infrastructure, strong corporate earnings, and a liquidity boost from the U.S. Federal Reserve (Fed). U.S. inflation remained contained, spurring the Fed to cut interest rates twice during the quarter. Amid a positive economic b...
Monty Rakusen/DigitalVision via Getty Images Market review and outlook Global equities rose in Q4, closing 2025 on a positive note. Markets gained on robust spending on AI infrastructure, strong corporate earnings, and a liquidity boost from the U.S. Federal Reserve (Fed). U.S. inflation remained contained, spurring the Fed to cut interest rates twice during the quarter. Amid a positive economic backdrop, the European Central Bank left rates unchanged, while easing inflation in the United Kingdom led the Bank of England to lower rates in December. As of year-end, uncertainty about central bank policy has eased and global monetary and fiscal measures remain supportive, although recent labor data has softened. Given improving investor sentiment and ongoing divergence among equity markets, we maintain a constructive outlook that, in our view, may provide a favorable environment for bottom-up stock selection. Contributors and detractors The fund outperformed the benchmark, the MSCI All Country World ex-USA Growth Index. Security selection meaningfully contributed, especially in financials, communication services, and healthcare. However, sector allocation, which results from our bottom-up (stock-by-stock) investment approach, was a partly offsetting factor, particularly an overweight in communication services and an underweight in IT. Regionally, strong selection in developed Europe and the Middle East (excluding the United Kingdom) and the United Kingdom contributed, even as unfavorable picks in Japan and North America detracted. The fund's biggest individual relative contributor was Taiwan Semiconductor Manufacturing Co., Ltd. ( TSM ), a contract semiconductor manufacturer. The company's shares rose during the quarter after the firm reported strong Q3 financial results, including a 10.1% revenue increase and a 39% year-over-year jump in earnings per share. Other relative contributors included Industria de Diseño Textil, S.A. (Inditex)( IDEXF ), a Spanish textile firm,...
JobRouter, a part of Aptean, has unveiled an enhancement to its low-code digital business process platform by integrating AI agents, enabling automation of complex tasks that were previously contingent on manual decision-making or cumbersome rule-based methods. These AI functionalities allow companies to efficiently automate workflows, integrating AI agents directly within processes to enhance dec...
JobRouter, a part of Aptean, has unveiled an enhancement to its low-code digital business process platform by integrating AI agents, enabling automation of complex tasks that were previously contingent on manual decision-making or cumbersome rule-based methods. These AI functionalities allow companies to efficiently automate workflows, integrating AI agents directly within processes to enhance decision-making processes and operational efficiency. With the release of version 2026.1,...